Immatics

Photo
18.09.2023 • News

Moderna and Immatics Collaborate on Cancer Therapies

US vaccine maker Moderna and German biotechnology company Immatics agreed on a broad multi-platform research and development collaboration for novel cancer therapies, combining Immatics’ TCR platform with Moderna’s mRNA technology. The project spans various therapeutic modalities including bispecifics, cell therapy and cancer vaccines.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.